Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.70 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.70 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.70 |
| ▸ | ALB | P02768 | 1/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | RARB | P10826 | 1/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.70 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.70 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3152241 | 1.00 | EPHX1 (1.00) | EPHX1CXCR1CXCR2PTGS1PTGS2 | |
| SCHEMBL1883571 | 1.00 | EPHX1 (1.00) | EPHX1CXCR1CXCR2PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL3424822 | 0.98 | EPHX1 (0.96) | EPHX1CXCR1CXCR2PTGS1PTGS2 | |
| SCHEMBL1082216 | 0.90 | EPHX1 (0.81) | EPHX1CXCR1CXCR2PTGS1PTGS2 | |
| SCHEMBL11641216 | 0.85 | EPHX1 (0.74) | EPHX1CXCR1CXCR2PTGS1PTGS2 | |
| SCHEMBL13802425 | 0.84 | EPHX1 (0.72) | EPHX1CXCR1CXCR2PTGS1PTGS2 | |
| SCHEMBL4471196 | 0.82 | CXCR1 (0.79) | EPHX1CXCR1CXCR2PTGS1PTGS2 | |
| Ibuprofen SCHEMBL239446 | 0.82 | PTGS1 (1.00) | EPHX1CXCR1CXCR2PTGS1PTGS2 | |
| SCHEMBL1526008 | 0.82 | EPHX1 (0.70) | EPHX1CXCR1CXCR2PTGS1PTGS2 | |
| SCHEMBL22509339 | 0.82 | EPHX1 (0.70) | EPHX1CXCR1CXCR2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4153177-A1 | ANTIFIBROTIC COMPOUNDS AND RELATED METHODS | Florida State University Research Foundation, Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| US-11548874-B2 | Antifibrotic compounds and related methods | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-01-10 | — | — | US | claimed |
| EP-1753734-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2007-02-21 | — | — | EP | claimed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | claimed |
| EP-0549710-B1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERIC 2-ALKANOIC ACIDS | DU PONT (US) | 1996-02-28 | — | — | EP | claimed |
| EP-0549710-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERIC 2-ALKANOIC ACIDS. | DU PONT (US) | 1993-07-07 | — | — | EP | claimed |
| EP-0537259-A1 | PROCESS FOR PRODUCING ENANTIOMERS OF 2-ARYL-ALKANOIC ACIDS | NOVO NORDISK A/S (DK) | 1993-04-21 | — | — | EP | claimed |
| WO-1992005275-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERIC 2-ALKANOIC ACIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-02 | — | — | WO | claimed |
| WO-1992001062-A1 | PROCESS FOR PRODUCING ENANTIOMERS OF 2-ARYL-ALKANOIC ACIDS | NOVO NORDISK A/S (DK) | 1992-01-23 | — | — | WO | claimed |
| US-4347373-A | Derivatives of 4-methyl-5-[(2-aminoethyl)-thiomethyl]-imidazole | TURCONI FRANCO | 1982-08-31 | — | — | US | claimed |
| US-4341798-A | ANTIINFLAMMATORY AGENT | LABORATORI PROPHIN S.P.A. (IT) | 1982-07-27 | — | — | US | claimed |
| CN-119504743-A | Naphthyridones compound, pharmaceutical composition and application thereof | 中国药科大学 | 2025-02-25 | — | — | CN | disclosed |
| EP-4476226-A1 | CONJUGATES OF CHEMOTHERAPY AGENTS AND TISSUE-BINDING SMALL MOLECULES, COMPOSITIONS AND METHODS THEREOF | Canwell Biotech Limited (CN) | 2024-12-18 | — | — | EP | disclosed |
| CN-118946569-A | Conjugates of chemotherapeutic agents and tissue-binding small molecules, compositions and methods | 康威(广州)生物科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-4272761-A2 | COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS | Medicon Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-1992005275-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERIC 2-ALKANOIC ACIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-02 | — | — | WO | disclosed |
| WO-1992001062-A1 | PROCESS FOR PRODUCING ENANTIOMERS OF 2-ARYL-ALKANOIC ACIDS | NOVO NORDISK A/S (DK) | 1992-01-23 | — | — | WO | disclosed |
| US-4347373-A | Derivatives of 4-methyl-5-[(2-aminoethyl)-thiomethyl]-imidazole | TURCONI FRANCO | 1982-08-31 | — | — | US | disclosed |
| US-4341798-A | ANTIINFLAMMATORY AGENT | LABORATORI PROPHIN S.P.A. (IT) | 1982-07-27 | — | — | US | disclosed |
| EP-0036684-A1 | Derivatives of 4-methyl-5-(2-aminoethyl)-thiomethyl-imidazole having therapeutic activity | Turconi, Franco (IT) | 1981-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548874-B2 | Antifibrotic compounds and related methods | COL1A1, COL2A1, COLGALT1 | EPHX1 661/4885CXCR1 1266/4885CXCR2 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.